Additionally, BM-MSCs treatment depicted a significant increase in VEGF expression by 136% compared to cardiotoxicity induced by NASH (Figure 4F,I,J). The gene discussed is VEGFA; the disease is metabolic dysfunction-associated steatohepatitis.